Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.21, Zacks reports.
Aerovate Therapeutics Stock Down 1.5 %
Shares of NASDAQ AVTE opened at $2.68 on Friday. The stock has a market capitalization of $77.68 million, a price-to-earnings ratio of -0.90 and a beta of 0.95. Aerovate Therapeutics has a 52 week low of $1.25 and a 52 week high of $25.29. The firm has a 50-day moving average price of $2.53 and a 200 day moving average price of $2.53.
Aerovate Therapeutics Dividend Announcement
The business also recently declared a dividend, which will be paid on Monday, April 28th. Stockholders of record on Friday, April 25th will be paid a dividend of $2.40 per share. The ex-dividend date of this dividend is Tuesday, April 29th.
About Aerovate Therapeutics
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Stories
- Five stocks we like better than Aerovate Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery
- What is a Special Dividend?
- O’Reilly Automotive: An Anytime Buy for Buy-and-Hold Investors
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
